T1	condition 14 23	bone loss
T2	intervention 29 40	risedronate
T3	total-participants 904 907	109
T4	eligibility 908 1040	postmenopausal women with low bone mass on an AI (anastrozole, letrozole, or exemestane) for hormone-receptor-positive breast cancer
T5	control 1107 1114	placebo
T10	outcome 1542 1552	at the hip
T16	outcome 1497 1509	at the spine
T6	outcome 1702 1706	P1NP
T9	outcome 1673 1676	CTX
T11	outcome 1765 1777	CTX and P1NP
T12	outcome 1356 1359	BMD
T8	outcome 1887 1910	safe and well tolerated
T7	outcome-Measure 1192 1195	BMD
T13	outcome-Measure 1197 1200	BTM
T14	outcome-Measure 1306 1312	safety
